Goldman Sachs Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $165

Benzinga Newsdesk www.benzinga.com Neutral 61.8%

Neg 0% Neu 61.8% Pos 0%

Goldman Sachs analyst Evie Koslosky initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $165.